

HOPE™ 1 & 2 FORMULATIONS

UNLOCKING THE POWER OF THE ENDOCANNABINOID SYSTEM IN US ALL

HOPE™ 1 & 2 are not listed on the Australian Register of Therapeutic Goods (ARTG) and are only available via Special Access Scheme (SAS A or SAS B) or Authorised Prescriber (AP) scheme, or clinical trials.

What is HOPE™?

HOPE™ 1 & 2 are part of a growing family of proprietary cannabinoid-based medicines produced by ZELIRA Therapeutics. Our formulations are created by extracting, isolating, and then reassembling the medicinal compounds from the cannabis plant (including cannabinoids and terpenes) to achieve specific and targeted effects.

What are cannabinoids?

Cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) are two of the most well-researched cannabinoids, which work synergistically to produce the pharmacologic and therapeutic effects of cannabinoid-based medicines.¹

What are terpenes?

Terpenes interact with cannabinoids, through the 'entourage effect' to strengthen and broaden clinical applications and improve the therapeutic index in cannabinoid-based medicines.¹

What is the endocannabinoid system?

The endocannabinoid system (ECS) is a widespread neuromodulatory system that plays an important role in central nervous system development and maintaining homeostasis.² The ECS is comprised of cannabinoid receptors, endogenous cannabinoids and enzymes responsible for the synthesis and degradation of endocannabinoids.² The pharmacological effects of cannabinoids on the body are a result of their ability to interact with cannabinoid receptors and modulate the ECS and its role in physiological and pathophysiological conditions.^{2,3}

ZELIRA Therapeutics premium cannabinoid-based medicines are:

- Clinically validated
- Proprietary formulations
- GMP grade
- Compliant with the standard for Medicinal Cannabis TGO93 Order 2017.

GMP: Good manufacturing practice.



HOPE™ 1 & 2 FORMULATIONS



Products are not intended to diagnose, treat, cure, or prevent any disease. Information is not intended as medical advice.

	HOPE™ 1	HOPE™ 2
Active ingredients	1 : 1 THC : CBD ratio THC (5 mg/mL) + CBD (5 mg/mL)	5 : 1 THC : CBD ratio THC (8.3 mg/mL) + CBD (1.7 mg/mL)
Excipients	Terpenes: • Alpha-pinene • Valencene • Eucalyptol A mild taste of mint.	Terpenes: • Beta-caryophyllene • Myrcene • Alpha-bisabolol A mild taste of grapefruit.
Formulation	Tincture blended with pharmaceutical grade refined, bleached and deodorised olive oil.	
Administration	Taken orally.	
Dosing	The optimal dose of HOPE™ has not been established. It is important to start with a low dose and increase as needed, to minimise the risk of side effects.	
Indications	HOPE™ should only be used to treat specific conditions/symptoms of an individual patient by an authorised medical practitioner as per the approval received.	
Clinical trial	A self-reported outcomes survey of patients with autism spectrum disorder (ASD) – data available on request. ⁴	

TO ACCESS ZELIRA THERAPEUTICS PRODUCTS

ZELIRA Therapeutics has partnered with Health House Holdings Ltd for the distribution of products in Australia.

T: 08 9444 2444 E: info@healthhouse.com.au W: healthhouse.com.au

For more information about accessing cannabinoid-based medicines, ZELIRA Therapeutics products, or to report an adverse event, contact:

T: 1300 ZELIRA (935 472) E: support@zeliratx.com W: www.zeliratx.com



[/zeliratx](https://www.facebook.com/zeliratx)



[/zeliratx](https://twitter.com/zeliratx)



[/zelira-therapeutics](https://www.linkedin.com/company/zelira-therapeutics)

References: 1. Russo EB. *Br J Pharmacol* 2011;163:1344–64. 2. Lu H-C and Mackie K. *Biol Psychiatry* 2016;79(7):516–25. 3. VanDolah HJ, et al. *Mayo Clin Proc* 2019;94(9):1840–51. 4. Data on File.

HOPE is a registered trademark of ZELIRA Therapeutics Ltd. ABN 27 103 782 378.
Level 26, 140 St Georges Terrace, Perth WA 6000. www.zeliratx.com.
Date of approval July 2020. ZEL-HOP-001.01.

A leading global cannabinoid-based medicines company

